MEA Stem Cell Therapy Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Middle East and Africa stem cell therapy market is projected to register a substantial CAGR of 4.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029

Market Segmentation:

Middle East and Africa Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (Israel) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Middle East and Africa stem cell therapy market are:

The rise in the incidence of chronic diseases such as musculoskeletal disorders

Rise in approval of stem cell therapeutics in Israel

Market Players:

Some of the major players operating in the Middle East and Africa stem cell therapy market are:

U.S. Stem Cell, Inc.

STEMPEUTICS RESEARCH PVT LTD

Pluristem Inc.

1 INTRODUCTION 19

1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 22

2 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: SEGMENTATION 24

2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 PRODUCT SEGMENT LIFELINE CURVE 31
2.8 DBMR MARKET POSITION GRID 32
2.9 VENDOR SHARE ANALYSIS 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 SECONDARY SOURCES 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 41

4.1 PESTEL 42
4.2 PORTER'S FIVE FORCES MODEL 43

5 EPIDEMIOLOGY 44

6 PIPELINE ANALYSIS FOR THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET 45

7 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: REGULATIONS 46

8 MARKET OVERVIEW 49

8.1 DRIVERS 51
- 8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 51
- 8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 52
- 8.1.3 GROWING BIOTECHNOLOGY SECTOR 53
- 8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 54
- 8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 54
8.2 RESTRAINTS 55
- 8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 55
- 8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 55
- 8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 56
- 8.2.4 AVAILABILITY OF ALTERNATIVES 56
8.3 OPPORTUNITIES 57
- 8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 57
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE 57
- 8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 58
8.4 CHALLENGES 58
- 8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 58
- 8.4.2 STRINGENT REGULATIONS 59

9 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE 61

9.1 OVERVIEW 62
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 65
9.3 PLACENTAL/UMBILICAL STEM CELL 65
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 66
9.5 OTHERS 67

10 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY TYPE 69

10.1 OVERVIEW 70
10.2 ALLOGENEIC STEM CELL THERAPY 73
- 10.2.1 MUSCULOSKELETAL DISORDERS 74
- 10.2.2 WOUNDS AND INJURIES 74
- 10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 74
- 10.2.4 SURGERIES 74
- 10.2.5 GASTROINTESTINAL DISEASES 74
- 10.2.6 OTHER APPLICATION 74
10.3 AUTOLOGOUS STEM CELL THERAPY 74
- 10.3.1 CARDIOVASCULAR DISEASES 76
- 10.3.2 GASTROINTESTINAL DISEASES 76
- 10.3.3 OTHER APPLICATION 76

11 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY APPLICATION 77

11.1 OVERVIEW 78
11.2 MUSCULOSKELETAL DISORDERS 80
11.3 WOUNDS AND INJURIES 81
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 82
11.5 SURGERIES 83
11.6 GASTROINTESTINAL DISEASES 84
11.7 CARDIOVASCULAR DISEASES 84
11.8 OTHER APPLICATION 85

12 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY END USER 87

12.1 OVERVIEW 88
12.2 HOSPITAL AND SURGICAL CENTERS 91
12.3 THERAPEUTIC COMPANIES 91
12.4 SERVICES COMPANIES 92
12.5 OTHERS 93

13 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 94

13.1 OVERVIEW 95
13.2 DIRECT TENDER 99
13.3 THIRD PARTY DISTRIBUTORS 99

14 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY REGION 101

14.1 MIDDLE EAST AND AFRICA 102
- 14.1.1 ISRAEL 108

15 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 110

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 110

16 SWOT ANALYSIS 111

17 COMPANY PROFILE 112

17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 112
- 17.1.1 COMPANY SNAPSHOT 112
- 17.1.2 REVENUE ANALYSIS 112
- 17.1.3 COMPANY SHARE ANALYSIS 113
- 17.1.4 PRODUCT PORTFOLIO 113
- 17.1.5 RECENT DEVELOPMENT 113

17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 114
- 17.2.1 COMPANY SNAPSHOT 114
- 17.2.2 REVENUE ANALYSIS 114
- 17.2.3 COMPANY SHARE ANALYSIS 115
- 17.2.4 PRODUCT PORTFOLIO 115
- 17.2.5 RECENT DEVELOPMENTS 115
17.3 ORTHOFIX MEDICAL INC. (2021) 116
- 17.3.1 COMPANY SNAPSHOT 116
- 17.3.2 REVENUE ANALYSIS 116
- 17.3.3 COMPANY SHARE ANALYSIS 117
- 17.3.4 PRODUCT PORTFOLIO 117
- 17.3.5 RECENT DEVELOPMENTS 117
17.4 MEDIPOST (2021) 119
- 17.4.1 COMPANY SNAPSHOT 119
- 17.4.2 REVENUE ANALYSIS 119
- 17.4.3 COMPANY SHARE ANALYSIS 120
- 17.4.4 PRODUCT PORTFOLIO 120
- 17.4.5 RECENT DEVELOPMENTS 120
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 122
- 17.5.1 COMPANY SNAPSHOT 122
- 17.5.2 REVENUE ANALYSIS 122
- 17.5.3 COMPANY SHARE ANALYSIS 123
- 17.5.4 PRODUCT PORTFOLIO 123
- 17.5.5 RECENT DEVELOPMENT 123
17.6 CORESTEM, INC. (2021) 124
- 17.6.1 COMPANY SNAPSHOT 124
- 17.6.2 REVENUE ANALYSIS 124
- 17.6.3 PRODUCT PORTFOLIO 125
- 17.6.4 RECENT DEVELOPMENT 125
17.7 PHARMICELL CO., LTD. (2021) 126
- 17.7.1 COMPANY SNAPSHOT 126
- 17.7.2 PRODUCT PORTFOLIO 126
- 17.7.3 RECENT DEVELOPMENTS 126
17.8 ANTEROGEN.CO., LTD (2021) 127
- 17.8.1 COMPANY SNAPSHOT 127
- 17.8.2 PRODUCT PORTFOLIO 127
- 17.8.3 RECENT DEVELOPMENTS 127

17.9 ATHERSYS, INC.(2021) 128
- 17.9.1 COMPANY SNAPSHOT 128
- 17.9.2 REVENUE ANALYSIS 128
- 17.9.3 PRODUCT PORTFOLIO 129
- 17.9.4 RECENT DEVELOPMENTS 129
17.10 BRAINSTORM CELL LIMITED (2021) 130
- 17.10.1 COMPANY SNAPSHOT 130
- 17.10.2 PRODUCT PORTFOLIO 130
- 17.10.3 RECENT DEVELOPMENTS 130
17.11 BIORESTORATIVE THERAPIES, INC. (2021) 132
- 17.11.1 COMPANY SNAPSHOT 132
- 17.11.2 REVENUE ANALYSIS 132
- 17.11.3 PRODUCT PORTFOLIO 133
- 17.11.4 RECENT DEVELOPMENTS 133
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 134
- 17.12.1 COMPANY SNAPSHOT 134
- 17.12.2 PRODUCT PORTFOLIO 134
- 17.12.3 RECENT DEVELOPMENTS 134
17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 136
- 17.13.1 COMPANY SNAPSHOT 136
- 17.13.2 REVENUE ANALYSIS 136
- 17.13.3 PRODUCT PORTFOLIO 137
- 17.13.4 RECENT DEVELOPMENT 137
17.14 MESOBLAST LTD (2021) 138
- 17.14.1 COMPANY SNAPSHOT 138
- 17.14.2 REVENUE ANALYSIS 138
- 17.14.3 PRODUCT PORTFOLIO 139
- 17.14.4 RECENT DEVELOPMENTS 139
17.15 PLURISTEM INC.(2021) 140
- 17.15.1 COMPANY SNAPSHOT 140
- 17.15.2 REVENUE ANALYSIS 140
- 17.15.3 PRODUCT PORTFOLIO 141
- 17.15.4 RECENT DEVELOPMENT 141
17.16 STEMPEUTICS RESEARCH PVT LTD 142
- 17.16.1 COMPANY SNAPSHOT 142
- 17.16.2 PRODUCT PORTFOLIO 142
- 17.16.3 RECENT DEVELOPMENTS 142

17.17 U.S. STEM CELL, INC. (2021) 144
- 17.17.1 COMPANY SNAPSHOT 144
- 17.17.2 REVENUE ANALYSIS 144
- 17.17.3 PRODUCT PORTFOLIO 145
- 17.17.4 RECENT DEVELOPMENT 145

18 QUESTIONNAIRE 146

19 RELATED REPORTS 149

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 59
TABLE 2 MIDDLE EAST & AFRICA BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 60
TABLE 3 MIDDLE EAST & AFRICA PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 61
TABLE 4 MIDDLE EAST & AFRICA ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 62
TABLE 5 MIDDLE EAST & AFRICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 63
TABLE 6 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 67
TABLE 7 MIDDLE EAST & AFRICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 68
TABLE 8 MIDDLE EAST & AFRICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 69
TABLE 9 MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 10 MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 70
TABLE 11 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 75
TABLE 12 MIDDLE EAST & AFRICA MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 76
TABLE 13 MIDDLE EAST & AFRICA WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 77
TABLE 14 MIDDLE EAST & AFRICA ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 15 MIDDLE EAST & AFRICA SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 16 MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 17 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 18 MIDDLE EAST & AFRICA OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 19 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 85
TABLE 20 MIDDLE EAST & AFRICA HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 86
TABLE 21 MIDDLE EAST & AFRICA THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 22 MIDDLE EAST & AFRICA SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 24 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 93
TABLE 25 MIDDLE EAST & AFRICA DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 94
TABLE 26 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 95
TABLE 27 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 101
TABLE 28 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 101
TABLE 29 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 101
TABLE 30 MIDDLE EAST AND AFRICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 101
TABLE 31 MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 102
TABLE 32 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 102
TABLE 33 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 102
TABLE 34 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 102
TABLE 35 ISRAEL STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 103
TABLE 36 ISRAEL STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 103
TABLE 37 ISRAEL ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
TABLE 38 ISRAEL AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
TABLE 39 ISRAEL STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 104
TABLE 40 ISRAEL STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 104
TABLE 41 ISRAEL STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 104

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET : SEGMENTATION 18
FIGURE 2 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: DATA TRIANGULATION 21
FIGURE 3 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: DROC ANALYSIS 22
FIGURE 4 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 23
FIGURE 5 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS 23
FIGURE 6 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS 24
FIGURE 7 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: DBMR POSITION GRID 26
FIGURE 8 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS 28
FIGURE 9 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: END USER COVERAGE GRID 29
FIGURE 10 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: SEGMENTATION 33
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 34
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET FROM 2022 TO 2029 35
FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET FROM 2022 & 2029 35
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET 44
FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022 45
FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020 46
FIGURE 17 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021 56
FIGURE 18 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 57
FIGURE 19 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 57
FIGURE 20 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 58
FIGURE 21 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, 2021 64
FIGURE 22 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION) 65
FIGURE 23 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029) 65
FIGURE 24 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE 66
FIGURE 25 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, 2021 72
FIGURE 26 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 73
FIGURE 27 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029) 73
FIGURE 28 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE 74
FIGURE 29 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, 2021 82
FIGURE 30 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION) 83
FIGURE 31 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029) 83
FIGURE 32 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE 84
FIGURE 33 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021 90
FIGURE 34 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 91
FIGURE 35 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 91
FIGURE 36 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 92
FIGURE 37 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: SNAPSHOT (2021) 97
FIGURE 38 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY COUNTRY (2021) 98
FIGURE 39 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029) 98
FIGURE 40 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029) 99
FIGURE 41 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022-2029) 99
FIGURE 42 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%) 104